Dieulafoy lesion

disease
On this page

Also known as Dieulafoy diseaseDieulafoy lesion (hemorrhagic) of stomach and duodenumDieulafoy's lesionExulceratio simplex Dieulafoy

Summary

Dieulafoy lesion (MONDO:0001427) is a disease. A subtype of stomach disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameDieulafoy lesion
Mondo IDMONDO:0001427
DOIDDOID:12070
ICD-10-CMK31.82
SNOMED CT109558001
UMLSC0341217
MedGen574250
Is cancer (heuristic)no

Also known as: Dieulafoy disease · Dieulafoy lesion (hemorrhagic) of stomach and duodenum · Dieulafoy’s lesion · Exulceratio simplex Dieulafoy

Disease family

This is a subtype of stomach disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorderstomach disorderDieulafoy lesion

Related subtypes (18): gastric ulcer, functional gastric disease, pylorospasm, cascade stomach, pyloric stenosis, gastric dilatation, stomach diverticulosis, gastritis, gastroesophageal reflux disease, hiatus hernia, stomach polyp, non-hypoproteinemic hypertrophic gastropathy, gastric neoplasm, angiodysplasia of stomach, achlorhydria, gastric intestinal metaplasia, gastric duplication, pyloric duplication

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.